newsfilter
← Earnings
Earnings Releases·

Iridex Corporation — Third Quarter 2026 Earnings Summary

  • Total revenue declined 19% year-over-year to $10.2 million, driven by weaker international demand and distributor inventory adjustments, while gross margin expanded to 42.4% from 32.1% in the prior year period.
  • Full-year 2026 revenue guidance was reduced to $46–$48 million (excluding Middle East revenue) from the previous $51–$53 million range, with adjusted operating expenses expected to remain flat between $19 million and $19.5 million.
  • Net loss narrowed to $1.4 million ($0.08 per share) from $1.6 million in the prior year, though non-GAAP adjusted EBITDA loss widened to $0.6 million from $0.1 million.
  • Strategic initiatives include a transition of major products to third-party contract manufacturers to drive margin expansion in 2027, a completed headquarters relocation yielding $600,000 in annualized savings, and an ongoing product line review to reprioritize resources toward profitable opportunities.
Company
IRIDEX CORP
Sector
Healthcare
Industry
Medical Devices